This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||PAR / Par Technology Corp. (698884103)|
|President & CEO||FOLEY DONALD H|
|Industry||Calculating and Accounting Machines, Except Electronic Computers|
|Institutional Shares||6,545,977 - 40.71%|
|Common Shares Outstanding||16,078,316 shares (as of 2018-03-31)|
|Institutional Value||$ 72,241,000 USD|
Institutional Stock Ownership and Shareholders()
Par Technology Corp. (NYSE:PAR) has 47 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,545,977 shares.
Largest shareholders include
Eliot Rose Asset Management Llc, Dimensional Fund Advisors Lp, Wellington Management Group LLP, Stone House Capital Management, LLC, Wedbush Securities Inc, Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Renaissance Technologies LLC, and Thomson Horstmann & Bryant Inc.
Par Technology Corp. (NYSE:PAR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/par"><img src="https://images.fintel.io/us-par-so.png" alt="PAR / Par Technology Corp. Institutional Ownership"><a>
|BRIDGEWAY CAPITAL MANAGEMENT INC||107,542||107,542||0.00||1,006||1,515||50.60|
|Acrospire Investment Management LLC||3,757||0||-100.00||32||0||-100.00|
|TFS CAPITAL LLC||22,286||0||-100.00||190||0||-100.00|
|ELIOT ROSE ASSET MANAGEMENT LLC||1,606,915||1,247,634||-22.36|
|Matarin Capital Management, LLC||11,167||0||-100.00||104,411||0||-100.00|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||30,335||30,335||0.00||284||427||50.35|
|RBF Capital, LLC||70,685||70,685||0.00||661||996||50.68|
|Stone House Capital Management, LLC||675,000||750,000||11.11||6,311||10,568||67.45|
|Friedberg Investment Management||95,130||37,850||-60.21||810||395||-51.23|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||40,849||576|
|EAM Investors, LLC||0||10,100||0||142|
|PERRITT CAPITAL MANAGEMENT INC||123,248||0||-100.00||1,152||0||-100.00|
|GEODE CAPITAL MANAGEMENT, LLC||27,309||27,309||0.00||255||384||50.59|
|O'SHAUGHNESSY ASSET MANAGEMENT, LLC||7,994||7,837||-1.96||75||110||46.67|
|Bank of New York Mellon Corp||12,463||15,641||25.50||116||220||89.66|
|GOLDMAN SACHS GROUP INC||10,789||152|
|Russell Investments Group, Ltd.||800||800||0.00||7||11||57.14|
|Wellington Management Group LLP||1,017,503||913,703||-10.20||9,514||12,874||35.32|
|BANK OF AMERICA CORP /DE/||0||2,200||0||31|
|GSA CAPITAL PARTNERS LLP||15,300||13,600||-11.11||143||192||34.27|
|ARROWSTREET CAPITAL, LIMITED PARTNERSHIP||36,594||27,394||-25.14||342||386||12.87|
|BANK OF MONTREAL /CAN/||0||81||0||1|
|Tower Research Capital LLC (TRC)||407||505||24.08||4||7||75.00|
|Municipal Employees' Retirement System of Michigan||43,500||43,500||0.00||613||769||25.45|
|Tibra Equities Europe Ltd||22,719||320|
|Cornerstone Advisors, Inc.||21||21||0.00||2||2||0.00|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||837||714||-14.70||8||10||25.00|
|Squarepoint Ops LLC||16,500||0||-100.00||154||0||-100.00|
|Renaissance Technologies LLC||227,100||166,300||-26.77||2,123||2,343||10.36|
|BlackRock Institutional Trust Company, N.A.||251,855||251,855||0.00||1,351||1,405||4.00|
|Granite Investment Partners, LLC||111,984||40,420||-63.91||1,047||569||-45.65|
|Sullivan, Bruyette, Speros & Blaney, Inc.||26,079||26,079||0.00||244||367||50.41|
|MILLENNIUM MANAGEMENT LLC||14,940||70,491||371.83||140||993||609.29|
|VANGUARD GROUP INC||400,082||432,739||8.16||3,741||6,098||63.00|
|BlackRock Advisors LLC||3,332||3,332||0.00||18||19||5.56|
|UBS Group AG||0||2,601||0||37|
|WELLS FARGO & COMPANY/MN||10,876||10,329||-5.03||101||145||43.56|
|THOMSON HORSTMANN & BRYANT INC||0||165,190||0||2,327|
|WEDBUSH SECURITIES INC||489,734||454,616||-7.17||4,579||6,406||39.90|
|Brasada Capital Management, Lp||130,580||123,030||-5.78||1,141||1,733||51.88|
|NORTHERN TRUST CORP||51,059||46,612||-8.71||477||656||37.53|
|ALGERT GLOBAL LLC||237,219||88,440||-62.72||2,218||1,246||-43.82|
|Raymond James Financial Services Advisors, Inc.||28,000||395|
|DIMENSIONAL FUND ADVISORS LP||921,978||921,226||-0.08||8,620||12,980||50.58|
|BlackRock Investment Management, LLC||1,764||1,764||0.00||9||10||11.11|
|MetLife Securities, Inc||3,000||0||-100.00||16||0||-100.00|
|THOMPSON DAVIS & CO., INC.||0||500||0||7|
|BlackRock Fund Advisors||27,365||28,161||2.91||147||157||6.80|
|DEUTSCHE BANK AG\||48,100||15,998||-66.74||449||225||-49.89|
|BlueCrest Capital Management Ltd||21,767||11,089||-49.06||204||156||-23.53|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Based on the aggregate numbers, there is nothing to warrant such a rise; in fact, one could say quite the contrary. (24-1)
Good day, ladies and gentlemen, and welcome to the PAR Technology Fiscal Year 2018 First Quarter Financial Conference Call. [Operator Instructions] As a reminder today's conference is being recorded. (6-0)
As I was reading Par Technology's (PAR) recent earnings call, something caught my eye--namely, this innocuous-sounding Q&A (italics added). (6-3)
After a period of mismanagement, the company is emerging with the first results of a new management, an acquisition, and a new strategy. (6-1)
PAR Technology Corporation (NYSE:PAR) Q4 2017 Results Earnings Conference Call March 15, 2018 4:30 PM ET (6-0)
as of ET